Overview
Prostatilen is a prostate-derived peptide complex originally developed in the Russian bioregulator tradition. It has been used in Russian medicine for chronic prostatitis, benign prostatic hyperplasia-related symptoms, and prostate function support. Unlike many obscure bioregulators, Prostatilen does have older clinical literature, including a Russian trial in chronic prostatitis, but it is still not FDA-approved.
The proposed mechanism is organ-specific peptide regulation of prostate tissue, with possible effects on inflammation, edema, microcirculation, leukocyte activity, and smooth muscle tone. Product forms in Russia have included injectable preparations and suppositories. These forms should not be assumed equivalent to research peptides sold online.
Prostatilen is not FDA-approved for prostatitis, BPH, pelvic pain, urinary symptoms, fertility, or prostate cancer prevention. Prostate symptoms require evaluation because infection, urinary retention, neurologic bladder dysfunction, medication effects, BPH, and malignancy can overlap. PSA interpretation and prostate exams should remain clinician-guided.
This guide puts Prostatilen in context: useful historical signal, limited modern evidence, important route differences, safety questions, and the practical need to distinguish chronic bacterial prostatitis from chronic pelvic pain syndrome and BPH.
Quick facts
- Mechanism
- Prostate-derived peptide complex with anti-inflammatory claims
- Primary use
- Prostatitis and prostate symptom research
- Evidence
- limited
- FDA
- Not approved
- Route
- Intramuscular injection or rectal suppository in regional products
- Typical results
- Symptom improvement reported in older Russian clinical studies
Chemical information
Prostatilen is described as a prostate-derived peptide complex with approximate molecular mass around 500 g/mol. Because it is a complex rather than one sequence, the chemical formula is formulation-dependent and listed as a peptide complex.
How Prostatilen works
Prostatilen is proposed to act as a tissue-specific peptide bioregulator for the prostate. Older clinical and experimental reports describe improvements in pain, urination, inflammatory markers, and prostate-related symptoms. The exact active components are not fully defined in a single sequence, so the mechanism is best understood as a peptide complex rather than a receptor-specific drug.
Chronic prostatitis is not one disease. Bacterial prostatitis, inflammatory chronic pelvic pain syndrome, non-inflammatory pelvic pain, and BPH-related lower urinary tract symptoms can feel similar but require different management. This makes Prostatilen studies hard to generalize unless diagnosis, cultures, symptom scores, and follow-up are clearly reported.
The older Russian trial literature suggested good tolerability and symptomatic benefit with intramuscular Prostatilen. However, those studies predate many modern trial standards and may not map cleanly onto current NIH prostatitis categories. That does not make the data useless, but it does require restraint in interpretation.
Mechanistic claims include reduced prostate edema, improved local circulation, modulation of inflammatory cell activity, and tissue-specific normalization. For users, the practical question is whether symptoms, urinalysis, cultures, post-void residual, PSA context, and clinician findings improve, not whether a product matches marketing language.
- Peptide complex: Derived from animal prostate tissue rather than one defined short sequence
- Regional clinical use: Used in Russian medical practice, but not FDA-approved
- Inflammation focus: Proposed to reduce prostate inflammation and edema
- Symptom endpoints: Pain, urination, and sexual symptoms need structured tracking
- Diagnosis dependent: Bacterial prostatitis, CP/CPPS, and BPH are not interchangeable
- Formulation matters: Injectable, suppository, and vendor peptides may differ substantially
Pharmacokinetics
No modern FDA-style human PK profile was found for Prostatilen. Route, formulation, extraction method, and peptide composition likely affect exposure, so vendor products should not be assumed equivalent to regional medicines.
| Parameter | Value | Significance |
|---|---|---|
| Composition | Peptide complex | Multiple components complicate PK |
| Approved US dosing | None | Not FDA-approved |
| Historical routes | Intramuscular, rectal | Route changes may alter effects and safety |
| Human half-life | Not established | No validated dosing interval |
| Metabolism | Likely proteolytic degradation | Expected but not quantified |
| Monitoring | Symptoms, urine testing, cultures, PSA context | Objective diagnosis drives safety |
Dosing & administration
Older Russian clinical use involved specific regulated products and routes, including intramuscular injection courses. That should not be converted into dosing advice for research peptides or compounded products without medical oversight.
Before considering any prostate peptide, users should clarify the diagnosis. Fever, acute urinary retention, severe pelvic pain, blood in urine, recurrent urinary infections, or elevated PSA require prompt clinical evaluation.
If Prostatilen is studied, symptom scores, urinalysis, cultures when indicated, urinary flow, post-void residual, and clinician follow-up are more meaningful than subjective prostate comfort alone.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Prostatilen has more historical clinical use than many bioregulators, but it remains unapproved in the United States and should not delay evidence-based evaluation or treatment of prostatitis, BPH, urinary retention, or cancer concerns.
Common
- • Injection site pain
- • Rectal irritation with suppositories
- • Mild allergy-like symptoms
- • Headache
- • Digestive discomfort
- • Transient urinary symptom fluctuation
Serious / potential risks
- • Allergic reaction to animal-derived peptides
- • Delayed treatment of bacterial prostatitis
- • Missed urinary retention or prostate cancer evaluation
- • Contamination from unregulated injections
- • Unknown safety with chronic unsupervised use
Drug interactions
Formal interaction studies are limited; recommendations are based on prostate symptom management and route-related safety.
| Medication | Interaction | Recommendation |
|---|---|---|
| Antibiotics | Should not replace treatment for bacterial prostatitis | Use cultures and clinician guidance |
| Alpha-blockers | Overlapping urinary symptom endpoints | Monitor blood pressure and urinary response |
| 5-alpha-reductase inhibitors | BPH markers and PSA interpretation may be affected by standard therapy | Keep prescriber informed |
| Anticoagulants | Injection or rectal irritation may increase bleeding concern | Use caution |
| NSAIDs | May mask pain and inflammation changes | Track symptoms and avoid overuse |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Imported regional products | Variable | Legality and authenticity depend on jurisdiction |
| Research peptide vendors | No standardized pricing | Not equivalent to approved regional medicines |
| Urology care | Insurance dependent | Diagnostic evaluation is often more valuable than supplements |
The bottom line
Prostatilen is one of the better-documented Khavinson-style peptide complexes, with older Russian clinical use for chronic prostatitis. Still, it is not FDA-approved, product forms vary, and prostate symptoms deserve proper diagnosis before any peptide experiment.
Best for
- • Researchers studying prostate peptide complexes
- • Clinician-supervised prostatitis adjunct research
- • Users with a clear diagnosis and monitoring plan
- • Historical bioregulator literature review
Not for
- • Acute bacterial prostatitis without antibiotics
- • Unexplained elevated PSA without evaluation
- • Urinary retention
- • DIY injection from unverified vendors
Related compounds
Pancragen
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenibut
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenibut FAA
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenylpiracetam
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Tkachuk VN, Gorbachev AG, Khavinson VKh. The use of prostatilen in treating patients with chronic prostatitis. Urologiia i Nefrologiia (1991). PMID: 1823682
- [2] Nickel JC. Prostatitis. Canadian Urological Association Journal (2011). PMID: 22031635
- [3] Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU International (2015). doi: 10.1111/bju.13101 PMID: 25711488
- [4] Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules (2021). doi: 10.3390/molecules26227053 PMID: 34834147
- [5] Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology (2010). doi: 10.1007/s10522-009-9249-8 PMID: 19830585
- [6] American Urological Association. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia. AUA Guideline (2023).